Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
1366057 | Bioorganic & Medicinal Chemistry Letters | 2007 | 5 Pages |
Abstract
This communication details the evolution of the screening lead SB-203580, a known CSBP/p38 kinase inhibitor, into a potent and selective Tie2 tyrosine kinase inhibitor. The optimized compound 5 showed efficacy in an in vivo model of angiogenesis and a MOPC-315 plasmacytoma xenograft model.
Graphical abstractThe synthesis and in-depth evaluation of compound 5, an inhibitor (IC50 = 250 nM) of Tie2 kinase, is described.Figure optionsDownload full-size imageDownload as PowerPoint slide
Related Topics
Physical Sciences and Engineering
Chemistry
Organic Chemistry
Authors
Marcus Semones, Yanhong Feng, Neil Johnson, Jerry L. Adams, Jim Winkler, Michael Hansbury,